Introduction {#s1}
============

*Streptococcus pyogenes*, ranked as one of the top 10 infectious causes of death worldwide, is responsible for more than 517,000 deaths annually (Carapetis et al., [@B5]). Also known as group A *Streptococcus* (GAS), it can cause various clinical infections, such as pharyngitis, impetigo, scarlet fever, necrotizing fasciitis, streptococcal toxic shock syndrome, and the immune mediated post-infectious manifestations of acute post-streptococcal glomerulonephritis, acute rheumatic fever and rheumatic heart disease (Walker et al., [@B41]). Since 2011, an unexpected pediatric scarlet fever epidemic has occurred and sustained in Hong Kong and throughout mainland China, with an incidence of 22--31 cases per 100,000 people (Chen et al., [@B9]; Lau et al., [@B18]; Tse et al., [@B36]; Yang et al., [@B44]; Davies et al., [@B11]). Furthermore, an ongoing scarlet fever outbreak has been reported in the United Kingdom since 2013/2014 season (Chalker et al., [@B7]), with an incidence of 25 cases per 100,000 people.

Penicillin and macrolides are primary antibiotic therapeutics administered for suspected *S. pyogenes* infections (Montes et al., [@B23]). Although *S. pyogenes* remains susceptible to penicillin, resistance to macrolides is increasing and a major cause for concern in China, with a frequency \>93% (Chen et al., [@B9]; Yang et al., [@B44]). Fluoroquinolones (FQs) are an attractive alternative when patients are hypersensitive to beta-lactam antibiotics (Montes et al., [@B23]). In China, consumption of FQs increased by up to 2 × 10^8^ standard units during 2001--2010, becoming the third most consumed antibiotic in the adult population (Van Boeckel et al., [@B37]). Increasing frequencies of *S. pyogenes* isolates with reduced susceptibility to FQs have been observed in many countries (Reinert et al., [@B31]; Malhotra-Kumar et al., [@B21]; Smeesters et al., [@B34]; Montes et al., [@B23]; Pires et al., [@B28]; Van Heirstraeten et al., [@B38]; Petrelli et al., [@B26]), yet data on FQ-non-susceptible *S. pyogenes* in China remain scarce despite extremely high resistance to primary interventions such as macrolides.

In Gram-positive bacteria, FQ resistance is mainly mediated through point mutations within the quinolone resistance-determining region (QRDR) of topoisomerase IV ParC and ParE and /or the topoisomerase II DNA gyrase GyrA and GyrB and efflux pump (Hooper, [@B14]). In *S. pyogenes*, FQ resistance is reported to be conferred by either *parC* or *gyrA* (Yan et al., [@B42]; Albertí et al., [@B1]; Montes et al., [@B23]), and develop in a stepwise manner (Malhotra-Kumar et al., [@B22]). At first, mutations occurring in *parC* can lead to low-level resistance. Then, additional mutations in *gyrA* can lead to high-level resistance. Mutations in the *parC* and *gyrA* QRDRs can occur not only spontaneously but also by means of horizontal gene transfer from other streptococcal species (Pletz et al., [@B29]; Duesberg et al., [@B12]; Pinho et al., [@B27]).

The aim of this study was to investigate the frequency, mechanism, and epidemiological association of FQ non-susceptibility in *S. pyogenes* during 2011 and 2016 from Shanghai, China.

Materials and methods {#s2}
=====================

Isolate database
----------------

In order to generate a *S. pyogenes* isolate database representative of the Shanghai population, carriage, and clinical isolates were prospectively collected from different geographical locations in Shanghai between June 2011 to June 2016. A total of 2,258 isolates were collected, of which 2,230 were from children ≤15 years old and 28 from adults. The database including 2,094 clinical isolates and 164 carriage isolates mostly from healthy students in schools. Clinical isolates were primarily from pediatric patients presenting with scarlet fever (*n* = 1,717), tonsillitis (*n* = 355), invasive infections (*n* = 1), or Henoch-Schonlein purpura (*n* = 1). *S. pyogenes* isolates were confirmed by latex-agglutination with the Diagnostic Streptococcal Grouping Kit (Oxoid, Hampshire, UK) and Vitek 2 system (bioMérieux, Marcy l\'Etoile, France). All 2,258 isolates were tested for fluoroquinolone resistance.

Molecular typing and genomic fingerprinting of *S. pyogenes*
------------------------------------------------------------

All isolates were characterized by *emm* type according to the standard protocol of Centers for Disease Control and Prevention (CDC; <http://www.cdc.gov/streplab/protocol-emm-type.html>). Pulsed-field gel electrophoresis (PFGE), a method involving chromosomal DNA macrorestriction, was performed to describe the genomic relationships among the GAS population using restriction endonuclease *Sma*I (TaKaRa, Dalian, China). PFGE patterns were analyzed using BioNumerics software package (version 6.5; Applied Maths, Austin, TX, USA) under the unweighted pair group method and an arithmetic averages (UPGMA) clustering algorithm, with settings as 1.0% optimization and 1.5% band tolerance (Carrico et al., [@B6]) As recommended in Hong Kong scarlet fever outbreak investigation (Tse et al., [@B36]), isolates with 80% similarity of PFGE bands were assigned to the same cluster. In the same cluster, isolates with indistinguishable PFGE pattern (no different bands) were assigned to the same clone.

FQs susceptibility test
-----------------------

Minimum inhibitory concentration (MIC) of levofloxacin was determined and interpreted with the broth microdilution method procedure recommended by the Clinical and Laboratory Standards Institute (CLSI) guidelines published in 2015 (Clinical and Laboratory Standards Institute, [@B10]). According to the breakpoints in CLSI 2015, FQ susceptibility were defined as susceptible, intermediate-resistant, and resistant when the isolates with MIC to levofloxacin as ≤2μg/ml, 4μg/ml, and ≥8μg/ml. *S. pyogenes* FQ non-susceptibility was defined as intermediate-resistant and resistant isolates. Efflux pump activity in the FQ non-susceptible isolates was investigated by the agar dilution method according to CLSI 2015 guidelines, comparing the MICs to levofloxacin and ciprofloxacin in the presence or absence of 30 μg/ml reserpine (Sigma-Aldrich), an efflux pump blocker (Jones et al., [@B16]). When a FQ-non-susceptible isolate showed a four-fold or greater decrease in the MIC to levofloxacin or ciprofloxacin, the efflux phenotype was deemed to be positive, which supported the involvement of the efflux mechanism (Jones et al., [@B16]).

Sequencing of quinolone resistance-associated genes
---------------------------------------------------

The QRDR sequences of genes encoding the topoisomerase IV(*parC* and *parE*) and the gyrase (*gyrA* and *gyrB*) were amplified and sequenced as previously described (Jones et al., [@B16]). Sequences of *parC* (accession number [AF220946](AF220946): position 64--561), *parE* (accession number [AE004092](AE004092): 752342--754294), *gyrA* (accession number [AF220945](AF220945): 79--540) and *gyrB* (accession number [AE004092](AE004092): 581675--583627) from the quinolone-susceptible *S. pyogenes* strain SF370 (ATCC 700294) were defined as reference alleles (Malhotra-Kumar et al., [@B21]). The genome sequences of *S. pyogenes* isolates from Hong Kong and mainland China and the QRDR sequence of *parC* from 2 *S. pneumonia*, 7 *S. agalactiae*, 21 *S. dysgalactiae*, 1 *S. canis*, 1 *S. iniae*, 1 *S. porcinus*, 2 *S. equi*, and 1 *S. difficilis* isolates were retrieved from GenBank with the accession number listed in Tables [S1](#SM1){ref-type="supplementary-material"}, [S2](#SM1){ref-type="supplementary-material"}, respectively. The Lasergene software package (version 7.1; DNASTAR, Wisconsin, USA) was used to analyze nucleotide sequences and the deduced amino acid sequences. MEGA 5 (<http://www.megasoftware.net/>) was used to generate multi-sequence alignments and Neighbor-joining phylogenetic analysis. Clades were determined with the bootstrap values \>75% in the bootstrap test with 1,000 replicates. The evolutionary distances were computed by the Kimura two-parameter method and are in the units of the number of base substitutions per site.

Detection of other resistance-associated genes
----------------------------------------------

Genes associated with macrolide resistance (*ermB, ermA*, and *mef*) and tetracycline resistance (*tetM* and *tetO*) were screened by PCR using primers and reaction parameters as previously described (Pérez-Trallero et al., [@B25]).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS (version 20.0; IBM). Fisher\'s exact test was used for the comparison of FQ resistance frequency between isolates from children and adults. Statistical significance was assessed at *P* \< 0.05.

Accession numbers
-----------------

The sequences of the *parC* alleles defined in this study were submitted to GenBank under accession numbers [MF278797](MF278797) to [MF278806](MF278806), while the *parE* QRDR sequences of the 30 FQ-non-susceptible isolates as MG894399 to MG894428.

Ethical aspects
---------------

All GAS isolates characterized in this study were collected from GAS infection cases and their close contacts, as part of routine clinical management of patients and Shanghai surveillance system for scarlet fever, according to guidelines of infectious diseases used in China nationwide. Informed consent from patients and close contacts was approved by Shanghai Municipal Center for Disease Control and Prevention ethical review committee (No: 2016-4) (Chen et al., [@B8]).

Results {#s3}
=======

FQs susceptibility of *S. pyogenes*
-----------------------------------

A total of 2,258 *S. pyogenes* isolates were collected during 2011--2016, including 2,230 isolates from children ≤15 years old and 28 from adults. There were 30 (1.3%) FQ-non-susceptible isolates; 15 resistant (MIC range 8--16μg/ml) and 15 intermediate-resistant (MIC = 4μg/ml) isolates. The 30 isolates were all from clinical patients. Frequencies of FQ-non-susceptible isolates were different between children and adults (1.2 and 14.3%, respectively; *P* \< 0.05). Among the 1,717 isolates from scarlet fever patients, 24 (1.4%) were non-susceptible to FQs. The FQ-non-susceptible isolates were discovered every year during 2011--2016, with the frequency fluctuating between 2.4% in 2011 and 0.9% in 2016 (Figure [1](#F1){ref-type="fig"}). Alarmingly, twenty-four (80%) of the 30 FQ-non-susceptible isolates were also resistant to erythromycin (\>128μg/ml), clindamycin (\>128μg/ml), and tetracycline (8-32μg/ml) (Table [1](#T1){ref-type="table"}), and were identified to carry the resistance-associated genes *ermB* and *tetM*, while another isolate was resistant to only FQs and tetracycline (32μg/ml), possessing *tetM*.

![Frequency and *emm*-type distribution of fluoroquinolone non-susceptibility in *S. pyogenes* strains isolated between 2011 to 2016 from Shanghai, China.](fmicb-09-00542-g0001){#F1}

###### 

Antimicrobial susceptibility of isolates with different *emm* types.

  ***emm* type**                           **Total no. of isolates (%)**   **No. of FQ- non-susceptible isolates (%)[^a^](#TN1){ref-type="table-fn"}**   **No. of isolates resistant to macrolides, tetracycline, and FQ (%)[^b^](#TN2){ref-type="table-fn"}**   **Mutations in FQ-non-susceptible isolates (n)**                                     **MIC to levofloxacin (μg/ml)[^c^](#TN3){ref-type="table-fn"}**                         
  ---------------------------------------- ------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------- ---- ---- ------------
  *emm*1                                   816 (36.1)                      1 (0.1)                                                                       1 (0.1)                                                                                                 S79F (1)                                                                             no                                                                            no   no   4
  *emm*6                                   6                               6 (100)                                                                       6 (100)                                                                                                 S79A (6)                                                                             A378T (5)                                                                     no   no   4--8
  *emm*11                                  4                               4 (100)                                                                       4 (100)                                                                                                 S79F (4)                                                                             S402L (3)                                                                     no   no   4--16
  *emm*12                                  1362 (60.3)                     15 (1.1)                                                                      9 (0.7)                                                                                                 S79F (6), S79Y (8), D83V (1), A121V (15)                                             no                                                                            no   no   4--16
  *emm*87                                  1                               1 (100)                                                                       1 (100)                                                                                                 S79F (1)                                                                             E360D (1), V377L (1), H380N (1)                                               no   no   4
  *emm*89                                  15                              2 (13.3)                                                                      2 (13.3)                                                                                                D78A (1), D91N (2), S140P (2)                                                        E360D (2), D438N (1), D493N (2)                                               no   no   4--8
  *emm*94                                  1                               1 (100)                                                                       1 (100)                                                                                                 D83V (1)                                                                             no                                                                            no   no   4
  Others[^d^](#TN4){ref-type="table-fn"}   53                              0                                                                             0                                                                                                       no                                                                                   no                                                                            no   no   ≤ 0.25--2
  Total                                    2258                            30 (1.3)                                                                      24 (1.1)                                                                                                D78A (1), S79A (6), S79F (12), S79Y (8), D83V (2), D91N (2), A121V (15), S140P (2)   E360D (3), V377L (1), A378T (5), H380N (1), S402L (3), D438N (1), D493N (2)   no   no   ≤ 0.25--16

*FQ, fluoroquinolone*.

*Resistance to macrolides and tetracycline in all tested isolates was associated with ermB and tetM gene carriage, respectively*.

*MIC, minimum inhibitory concentration*.

*Other emm type isolates included 2x emm3, 3x emm4, 12x emm5, 10x emm22, 10x emm75, 1x emm103, 13x emm170, 1x emm203, and 1x emm227 isolates*.

Molecular epidemiology of FQ-non-susceptible *S. pyogenes*
----------------------------------------------------------

Molecular typing of the 2,258 isolates identified 16 *emm* types, with *emm*12 and *emm*1 isolates constituting 60.3 and 36.1% of the isolates respectively (Table [1](#T1){ref-type="table"}). The thirty FQ-non-susceptible isolates were assigned to seven *emm* types (Table [1](#T1){ref-type="table"}), including *emm*12 (1.1%, 15/1,362), *emm*6 (100%, 6/6), *emm*11 (100%, 4/4), *emm*89 (13.3%, 2/15), *emm*1 (0.1%, 1/712), *emm*87 (100%, 1/1), and *emm*94 (100%, 1/1). With the exception of 6 *emm*12 isolates, all FQ-non-susceptible *emm* types were resistant to both macrolides and tetracycline (Table [1](#T1){ref-type="table"}).

To examine the genomic relationships of the FQ-resistant population, genome fingerprinting of the 30 FQ-non-susceptible isolates by PFGE was performed. Six clusters (A-F) were observed (Figure [2](#F2){ref-type="fig"}). The *emm*6, *emm*11, and *emm*89 isolates were clonal as defined by an identical PFGE pattern whereas the *emm*12 family clustered into multiple subtypes.

![PFGE patterns of 30 fluoroquinolone-non-susceptible *S. pyogenes* strains isolated between 2011 to 2016 in Shanghai, China. Clusters A-F were assigned according to 80% similarity, and, isolates with indistinguishable pulsed-field gel electrophoresis (PFGE) pattern (no different bands) were assigned to the same clone. The numbers of similarity are labeled next to the branches.](fmicb-09-00542-g0002){#F2}

Characterization of FQ resistance mechanisms
--------------------------------------------

To examine the genetic basis of FQ-non-susceptibility, the *parC, parE, gyrA*, and *gyrB* sequences were sequenced and analyzed. Of the 30 FQ-non-susceptible isolates, all harbored at least one amino acid alteration in ParC, 11 (36.7%) harbored ParE mutations, and none had mutations in GyrA and GyrB QRDRs (Table [2](#T2){ref-type="table"}). In ParC, alteration at the amino acid site 79 (Ser) was found in 26 (86.7%) FQ-non-susceptible isolates, including S79A (*emm*6), S79F (*emm*1, *emm*11, *emm*12, and *emm*87), and S79Y (*emm*12). The mutation A121V was found in *emm*12 isolates irrespective of the FQ susceptibility. Less common mutations included D78A (1), D91N (2), S140P (2), and a novel mutation, D83V (2). A total of 9 *parC* nucleotide alleles were found in the 30 FQ-non-susceptible isolates, designated as SHparC1- SHparC9 (Table [2](#T2){ref-type="table"}). With the exception of SHparC6 that was represented by isolates of *emm*1 and *emm*87, each *parC* allele was represented by isolates of the same *emm* type. In ParE QRDRs, mutations of 7 amino acid sites were identified in 11 FQ-non-susceptible isolates (Table [2](#T2){ref-type="table"}), including E360D (3), V377L (1), A378T (5), H380N (1), S402L (3), D438N (1), and D493N (2). To further expand on these findings, we tested the efflux phenotype on all 30 FQ-non-susceptible isolates. None of the FQ-non-susceptible isolates showed a four-fold or greater decrease in the MIC to levofloxacin or ciprofloxacin after adding reserpine (30 μg/ml) indicating that the FQ tolerance could not be explained by the efflux pump mechanism.

###### 

Nucleotide changes identified in the quinolone resistance-determining regions of different *parC* alleles.

  ***parC* allele**                          **MIC to levofloxacin (μg/ml)[^a^](#TN5){ref-type="table-fn"}**   **No. of isolates**   ***emm* subtype**                **ParC mutation**                                                  **References to ParC with the same mutation pattern**
  ------------------------------------------ ----------------------------------------------------------------- --------------------- -------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SHparC1                                    4--8                                                              8                     12.0 (6), 12.76 (2)              S79Y (TCC→ TAC) A121V[^b^](#TN6){ref-type="table-fn"} (GCT→ GTT)   Malhotra-Kumar et al., [@B21]
  SHparC2                                    4--16                                                             6                     12.0 (3), 12.40 (1), 12.76 (2)   S79F (TCC→ TTC) A121V (GCT→ GTT)                                   Richter et al., [@B32]; Rivera et al., [@B33]; Lin et al., [@B19]
  SHparC3                                    4                                                                 1                     12.0 (1)                         D83V (GAT→ GTT) A121V (GCT→ GTT)                                   This study
  SHparC4                                    4--16                                                             4                     11.0 (3), 11.18 (1)              S79F (TCC→ TTC)                                                    Malhotra-Kumar et al., [@B21]; Orscheln et al., [@B24]; Biedenbach et al., [@B3]; Pletz et al., [@B29]; Montes et al., [@B23]; Arai et al., [@B2]
  SHparC5                                    4                                                                 1                     94.1 (1)                         D83V (GAT→ GTT)                                                    This study
  SHparC6                                    4                                                                 2                     1.56 (1), 87.0 (1)               S79F (TCC→ TTC)                                                    Wajima et al., [@B40]
  SHparC7                                    4--8                                                              6                     6.19 (2), 6.4 (4)                S79A (TCC→ GCC)                                                    Albertí et al., [@B1]; Malhotra-Kumar et al., [@B21], [@B22]; Orscheln et al., [@B24]; Powis et al., [@B30]; Rivera et al., [@B33]; Yan et al., [@B43]; Smeesters et al., [@B34]; Montes et al., [@B23]; Van Heirstraeten et al., [@B38]
  SHparC8                                    4                                                                 1                     89.0 (1)                         D91N (GAT→ AAT), S140P (TCT→ CCC)                                  Malhotra-Kumar et al., [@B21]
  SHparC9                                    8                                                                 1                     89.0 (1)                         D78A (GAT→ GCT), D91N (GAT→ AAT), S140P (TCT→ CCC)                 This study
  SHparC10[^c^](#TN7){ref-type="table-fn"}   ND[^d^](#TN8){ref-type="table-fn"}                                1                     1.0 (1)                          D83G (GAT→ GGT)                                                    Van Heirstraeten et al., [@B38]; Lin et al., [@B19]

*MIC, minimum inhibitory concentration*.

*A121V was also found in fluoroquinolone-susceptible isolates*.

*Sequence was extracted from the genome of HLJGAS2022*.

*ND, not determined*.

Conservation of ParC mutations within whole genome sequences from wider chinese clinical isolates
-------------------------------------------------------------------------------------------------

One hundred and seventy *S. pyogenes* genome sequences of isolates from Hong Kong (152) and mainland China (18) are publically available, including 136 *emm*12 and 34 *emm*1 strains isolated between 2004 to 2012. Examination of the QRDR genes identified 13 (7.6%) isolates with mutations in ParC QRDR, including 12 *emm*12 from Hong Kong belonging to three different evolutionary lineages and 1 *emm*1 isolates from mainland China (Heilongjiang Province), and no mutations within ParE, GyrA, and GyrB. The most common ParC mutation was S79F in ParC (SHparC2) with one *emm*1 isolate harboring alteration D83G in ParC, which was designated as a new *parC* allele: SHparC10.

Evolution of *parC* mutations within streptococcaceae
-----------------------------------------------------

Phylogenetic analysis involving 51 QRDR *parC* sequences from *S. pyogenes, S. pneumonia, S. agalactiae, S. dysgalactiae, S. canis, S. iniae, S. porcinus, S. equi*, and *S. difficilis* was performed to examine evidence of lateral gene transfer and FQ resistance. All *S. pyogenes* and *S. dysgalactiae* isolates clustered together into a single clade (Clade *S. pyogenes* & *S. dysgalactiae*, Figure [3](#F3){ref-type="fig"}). The clade can be further divided into two sub-branches: the *S. pyogenes* sub-branch and the *S. dysgalactiae* sub-branch. Most of the *S. pyogenes parC* alleles (8/10) defined in this study were grouped into *S. pyogenes* sub-branch, while alleles SHparC8 and SHparC9 were found in the *S. dysgalactiae* sub-branch. Five *parC* sequences of *S. dysgalactiae*, including FQ-susceptible and FQ-non-susceptible isolates, were included in the *S. pyogenes* sub-branch.

![Phylogenetic analysis of *parC* quinolone-resistance-determining region from different streptococcal species. Strains are shown as; species, strain number or *parC* allele; (*emm* type); country or district; and fluoroquinolone susceptibility. All fluoroquinolone-non-susceptible isolates were labeled with "R." Phylogenetic analysis was conducted in MEGA 5 using Neighbor-joining. Bootstrap values are indicated when support is \>75% (from 1,000 replicates). The tree is drawn to scale, with the branch lengths being in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed by the Kimura two-parameter method and are in the units of the number of base substitutions per site.](fmicb-09-00542-g0003){#F3}

Discussion {#s4}
==========

This study is the first report that investigates and characterizes FQ-non-susceptibility within *S. pyogenes* from mainland China during 2011--2016, the period overlapping an ongoing multidrug resistant GAS scarlet fever epidemic in China (Tse et al., [@B36]; Yang et al., [@B44]; Davies et al., [@B11]). We identified FQ non-susceptibility to be 1.3% in 2,258 GAS isolates from Shanghai, China, including within *emm*12 and *emm*1 scarlet fever clones resistant to macrolides and tetracycline. The appearance of these clones has further narrowed the choices of treatment for GAS infections. We observed a significant difference in FQ resistance frequencies in GAS isolated from adults (14.3%) compared to children (1.2%). This may in part be attributable to clinical practice where administration of fluoroquinolones is largely restricted to adults due to cartilage toxicity observed in children (Stahlmann et al., [@B35]).

Since 2006, very high frequencies (\>90%) of resistance to macrolide and tetracycline in GAS isolates have been reported in mainland China (Jing et al., [@B15]; Chen et al., [@B9]; Yang et al., [@B44]). Coincidently, fluoroquinolone consumption has increased over the last two decades and is currently the third most consumed antibiotic in China (Van Boeckel et al., [@B37]). Our study identified that 80% of FQ-non-susceptible isolates were also resistant to both macrolides (*ermB*) and tetracycline (*tetM*). In previous GAS studies, only three isolates harboring this multidrug resistance profile have been reported in a Belgian study (Malhotra-Kumar et al., [@B21]). With the emergence of antimicrobial resistance in respiratory pathogens intrinsically linked with antibiotic consumption (Goossens et al., [@B13]), the appearance of multidrug resistant clones through selective pressure is highly probable.

Compared with the prevalence of GAS FQ-non-susceptibility in Taiwan (11.1% in 2005--2012), Japan (14.1% in 2010--2012), Belgium (11.4% in 2007--2010), Spain (13% in 2005--2007), and USA (9% in 2003) (Yan et al., [@B43]; Montes et al., [@B23]; Van Heirstraeten et al., [@B38]; Wajima et al., [@B39]; Lin et al., [@B19]), the overall prevalence of FQ-non-susceptible *S. pyogenes* in Shanghai (1.3%) and Beijing (3.4%) (Yang et al., [@B44]) are relatively low. This may be attributed to the limited administration of FQ to pediatric patients in China, which constitute most of isolates in this study (98.8%) and all the isolates in the Beijing study. Correspondingly, low frequencies of FQ resistance was found in the most frequently isolated GAS *emm* type in this study, *emm*12 (1.1%). The frequencies of FQ resistance in *emm*12 isolates varies in different countries, from 0 (0/45) in Spain to 5% (1/20) in Japan, and to 50% (33/66) in Taiwan (Montes et al., [@B23]; Wajima et al., [@B39]; Lin et al., [@B19]). Based on whole genome analysis of scarlet fever isolates in Hong Kong (Davies et al., [@B11]), we estimate the frequency of *emm*12 FQ resistance in Hong Kong was 9.0% (12/134), of which 66.7% (8/12) were also resistant to macrolide and tetracycline possessing the corresponding molecular markers *ermB* and *tetM* (Table [S1](#SM1){ref-type="supplementary-material"}); however, validation of these findings through FQ susceptibility testing is required to confirm this genetic observation. The emergence of FQ resistance within ongoing scarlet fever epidemics in Hong Kong and mainland China (Luk et al., [@B20]; Yang et al., [@B44]) calls for more precaution when prescribing fluoroquinolones for suspected GAS infections.

In this study, FQ-non-susceptible *emm*6 isolates were discovered in China for the first time. Orscheln et al. proposed that FQ resistance is an intrinsic property of the *emm*6 lineage, with mutations in ParC driving FQs resistance long before the introduction of FQ antibiotics (Orscheln et al., [@B24]). The global dissemination of *emm*6 strains was suggested to be the main reason for the increased proportion of FQ-non-susceptible *S. pyogenes* in Belgium and Spain (Montes et al., [@B23]; Van Heirstraeten et al., [@B38]). All six *emm*6 isolates identified in this study were a single FQ-non-susceptible clone on the basis of PFGE, and harbored the same ParC QRDR S79A mutation (*parC* allele of SHparC7) with those *emm*6 isolates from USA and Spain (Orscheln et al., [@B24]; Rivera et al., [@B33]). In this study, the *emm*6 clone was also resistant to erythromycin, clindamycin, and tetracycline. This observation is mirrored for the global *emm*11 clone (Wajima et al., [@B40], [@B39]; Van Heirstraeten et al., [@B38]) with all four *emm*11 GAS isolated in this study representing a single FQ-non-susceptible clone harboring an S79F ParC mutation and the macrolide and tetracycline resistance markers. Collectively, monitoring for the global dissemination of these multidrug resistant GAS clones is warranted.

All FQ-non-susceptible *S. pyogenes* in this study showed a low-level resistance (MIC range, 4-16 μg/ml) and molecular analyses of the classic FQ-non-susceptibility genetic markers suggests that FQ-non-susceptibility in China is primarily linked to ParC QRDR mutations, for they all harbored ParC mutation(s), occasionally with ParE mutation(s), and none with GyrA and GyrB mutations or involvement of efflux pump, in addition, isolates with ParE mutation(s) showed similar MIC values to levofloxacin and ciprofloxacin compared to those only possessing ParC mutation(s). This supports the stepwise theory of FQ resistance: without GyrA mutation, where mutations in ParC only confer a low-level resistance (Billal et al., [@B4]). The most common alterations occurred in the amino acid site Ser79, a potential site to bind FQs (Laponogov et al., [@B17]), which is supported by findings from American and European countries (Orscheln et al., [@B24]; Smeesters et al., [@B34]). Polymorphisms of *parC* QRDR were found in FQ-non-susceptible isolates, and they were mostly linked with *emm* types in this study. This suggested most of the mutations might occur spontaneously within the strains\' evolutionary process, which was validated by the phylogenetic analysis of the *parC* QRDR however two *parC* alleles may have arisen through horizontal gene transfer from other streptococcal species such as *S. dysgalactiae*. Some *parC* sequence of FQ-susceptible and FQ-non-susceptible *S. dysgalactiae* were also grouped into the *S. pyogenes* sub-branch in this study, which provided more evidence for a global gene pool shared by *S. dysgalactiae* and *S. pyogenes* (Pinho et al., [@B27]). A number of ParE mutations were identified in this study, including three mutations of E360D, V377L, and H380N concurrently present in a *emm*87 isolate and an A378T mutation identified only in *emm*6 isolates as documented previously (Malhotra-Kumar et al., [@B21]; Lin et al., [@B19]), while S402L mutation was only found in *emm*11 isolates, and mutations of D438N and D493N were only identified in *emm*89 isolates, which were first reported in this study. These phenomena suggest most of the ParE mutations might be evolutionary linked with *emm* type rather than drivers of FQ resistance.

One limitation of this study is the small sample size of isolates from adults, which might lead to a possible bias when comparing the FQ-non-susceptibility frequency between isolates from children and adults, but the appearance of adult FQ-non-susceptible isolates in different years (2012 and 2013) supported, to some extent, the validation of the high frequency in adults. The lack of adult isolates can largely be attributed to the fact that only scarlet fever, which is primarily a disease of children, is the only notifiable disease among all the GAS infections in China (Yang et al., [@B44]). Another possible attribution might be that the morbidity of GAS infections is low in adults; however, more data on adult GAS infections in China is required to support this hypothesis (Chen et al., [@B8]). Our finding of a higher rate of FQ-non-susceptibility in isolates from adults (14.3%) is alarming and warrants further investigation at a population level.

In conclusion, the emergence of macrolide, tetracycline and fluoroquinolone- non-susceptible *S. pyogenes* in Shanghai, China during the period of scarlet fever epidemics was revealed in this study. Although FQ resistance was infrequent in mainland China, the presence of macrolide, tetracycline and fluoroquinolone multidrug-resistant clones across multiple *S. pyogenes emm* sequence types is alarming and the spread of these isolates should be monitored globally.
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